全文获取类型
收费全文 | 566170篇 |
免费 | 47719篇 |
国内免费 | 19730篇 |
专业分类
耳鼻咽喉 | 3869篇 |
儿科学 | 12438篇 |
妇产科学 | 7508篇 |
基础医学 | 85633篇 |
口腔科学 | 11007篇 |
临床医学 | 49511篇 |
内科学 | 87562篇 |
皮肤病学 | 7589篇 |
神经病学 | 38549篇 |
特种医学 | 13591篇 |
外国民族医学 | 166篇 |
外科学 | 47987篇 |
综合类 | 84606篇 |
一般理论 | 25篇 |
预防医学 | 33208篇 |
眼科学 | 10923篇 |
药学 | 62845篇 |
193篇 | |
中国医学 | 22257篇 |
肿瘤学 | 54152篇 |
出版年
2023年 | 6945篇 |
2022年 | 10398篇 |
2021年 | 17495篇 |
2020年 | 19339篇 |
2019年 | 24000篇 |
2018年 | 17319篇 |
2017年 | 18749篇 |
2016年 | 18754篇 |
2015年 | 20456篇 |
2014年 | 32322篇 |
2013年 | 36678篇 |
2012年 | 32732篇 |
2011年 | 37666篇 |
2010年 | 31571篇 |
2009年 | 30543篇 |
2008年 | 30383篇 |
2007年 | 30764篇 |
2006年 | 28023篇 |
2005年 | 25335篇 |
2004年 | 21762篇 |
2003年 | 18916篇 |
2002年 | 14977篇 |
2001年 | 13806篇 |
2000年 | 11414篇 |
1999年 | 10030篇 |
1998年 | 7586篇 |
1997年 | 6948篇 |
1996年 | 6153篇 |
1995年 | 6197篇 |
1994年 | 5501篇 |
1993年 | 4584篇 |
1992年 | 3952篇 |
1991年 | 3450篇 |
1990年 | 2892篇 |
1989年 | 2504篇 |
1988年 | 2297篇 |
1987年 | 1857篇 |
1986年 | 1615篇 |
1985年 | 2524篇 |
1984年 | 2571篇 |
1983年 | 1755篇 |
1982年 | 2005篇 |
1981年 | 1637篇 |
1980年 | 1440篇 |
1979年 | 1191篇 |
1978年 | 954篇 |
1977年 | 753篇 |
1976年 | 769篇 |
1975年 | 604篇 |
1974年 | 461篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
3.
4.
5.
6.
7.
Kari Hemminki MD PhD Kristina Sundquist MD PhD Jan Sundquist MD PhD Asta Försti PhD Vaclav Liska MD PhD Akseli Hemminki MD PhD Xinjun Li MD PhD 《Cancer》2023,129(8):1227-1236
Background
Autoimmune diseases are associated with many cancers but there is a lack of population-based studies with different autoimmune diseases that have a long follow-up. This is also true of hepatobiliary cancers, which include hepatocellular cancer (HCC) and rarer entities of gallbladder cancer (GBC), intra- and extrahepatic cholangiocarcinoma (iCCA and eCCA), and ampullary cancer.Methods
Diagnostic data on 43 autoimmune diseases were collected from the Swedish Inpatient Register from 1987 to 2018, and cancer data were derived from the national cancer registry from 1997 onward. Relative risks were expressed as standardized incidence ratios (SIRs).Results
In a population of 13.6 million, 1.1 million autoimmune diseases were diagnosed and subsequent hepatobiliary cancer was diagnosed in 3191 patients (17.2% of cancers). SIRs for HCC were 2.73 (men) and 2.86 (women), 3.74/1.96 for iCCA, 2.65/1.37 for GBC, 2.38/1.64 for eCCA, and 1.80/1.85 for ampullary cancer. Significant associations between autoimmune disease and HCC were observed for 13 autoimmune diseases, with the highest risks being for autoimmune hepatitis (48.92/73.53, men/women) and primary biliary cirrhosis (38.03/54.48). GBC was increased after six autoimmune diseases, with high SIRs for ulcerative colitis (12.22/3.24) and men with Crohn disease (9.16). These autoimmune diseases were also associated with a high risk of iCCA, which had seven other associations, and eCCA, which had five other associations. Ampullary cancer occurrence was increased after four autoimmune diseases.Conclusion
An autoimmune disease is a common precursor condition for hepatobiliary cancers. This calls for careful control of autoimmune disease symptoms in each patient and encouragement to practice a healthy lifestyle. 相似文献8.
9.